No Data
GTJA: The new paradigm reshapes the drug development landscape, and the cycle of inventory reduction for Active Pharmaceutical Ingredient is approaching its end.
The CXO adjustments are nearing completion, and the Industry is moving towards the development stage 2.0; the API destocking cycle is coming to an end, seizing opportunities for industrial transformation.
Trending Industry Today: TIGERMED Leads Gains In CRO Stocks
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Hong Kong stocks move | The CRO Concept collectively rises as the FDA previously released guidance documents for drug development AI, and several leading pharmaceutical companies announced AI drug manufacturing collaborations.
CRO Concept stocks have collectively risen; as of the time of writing, VIVA BIOTECH (01873) is up 6.82%, priced at 0.94 HKD; PHARMARON (03759) is up 4.3%, priced at 15.54 HKD; TIGERMED (03347) is up 3.9%, priced at 30.6 HKD; WUXI BIO (02269) is up 2.58%, priced at 21.9 HKD.
Hong Kong stocks movement | CRO Concept stocks rose broadly in the morning as Innovative Drugs continue to expand overseas. The Global interest rate cuts help improve CXO overseas Business.
CRO Concept stocks experienced a general rise in the morning session. As of the time of writing, FRONTAGE (01521) rose by 5.88%, trading at 1.8 HKD; WUXI APPTEC (02359) rose by 4.97%, trading at 57 HKD; WUXI BIO (02269) rose by 3.64%, trading at 18.2 HKD; PHARMARON (03759) rose by 3.21%, trading at 14.14 HKD.
【Brokerage Focus】CITIC SEC指出今年是在底部布局医疗健康产业优秀赛道和头部核心企业的最佳机会.
Golden Owl Finance | CITIC SEC stated that the 43rd J.P. Morgan Healthcare Conference will be held from January 13 to 16, 2025, in San Francisco, USA. As the largest and most content-rich healthcare investment seminar in the industry, it brings together global industry leaders, rapidly growing emerging companies, innovative technology creators, and investment professionals. According to the exchanges disclosed by participating companies, specifically, in the area of Innovative Drugs, the technological iteration and business development around core products/fields remain the growth engines for Pharma; in the CXO and upstream life sciences sector, upstream research and development needs are showing moderate recovery.
Expand
102884128 : getting disappointed with this counter. every day drop.